Since its inception, Pherecydes Pharma benefits of the financial support from various regional, national and European organizations.
European Commission, SME intrument Horizon H2020 program.
European Commission – 7th Framework Program for Research and Development (FP7);
DGA (Directorate General of Armaments) - a first RAPID-Duale grant, for the initial R&D to preclinical steps of the project (PACOBURNS).
DGA (Directorate General of Armaments) - a second RAPID-Duale grant for preclinical research up to clinical testing regulatory approval.
Ile-de-France Region and Seine-Saint-Denis Department, under the 18th FUI (Unique Intermininisterial Fund) call;
Bpifrance (French public bank of investment), for the future clinical trial planned in humans.
PHOSA also benefits from labeling by two French national clusters: Medicen Paris and Lyon Biopôle.